Christiansen Jason J, Rajasekaran Sigrid A, Inge Landon, Cheng Lirong, Anilkumar Gopalakrishnapillai, Bander Neil H, Rajasekaran Ayyappan K
Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095, USA.
Mol Cancer Ther. 2005 May;4(5):704-14. doi: 10.1158/1535-7163.MCT-04-0171.
Prostate-specific membrane antigen (PSMA) is an important biomarker expressed in prostate cancer cells with levels proportional to tumor grade. The membrane association and correlation with disease stage portend a promising role for PSMA as an antigenic target for antibody-based therapies. Successful application of such modalities necessitates a detailed knowledge of the subcellular localization and trafficking of target antigen. In this study, we show that PSMA is expressed predominantly in the apical plasma membrane in epithelial cells of the prostate gland and in well-differentiated Madin-Darby canine kidney cells. We show that PSMA is targeted directly to the apical surface and that sorting into appropriate post-Golgi vesicles is dependent upon N-glycosylation of the protein. Integrity of the microtubule cytoskeleton is also essential for delivery and retention of PSMA at the apical plasma membrane domain, as destabilization of microtubules with nocodazole or commonly used chemotherapeutic Vinca alkaloids resulted in the basolateral expression of PSMA and increased the uptake of anti-PSMA antibody from the basolateral domain. These results may have important relevance to PSMA-based immunotherapy and imaging strategies, as prostate cancer cells can maintain a well-differentiated morphology even after metastasis to distal sites. In contrast to antigens on the basolateral surface, apical antigens are separated from the circulation by tight junctions that restrict transport of molecules across the epithelium. Thus, antigens expressed on the apical plasma membrane are not exposed to intravenously administered agents. The ability to reverse the polarity of PSMA from apical to basolateral could have significant implications for the use of PSMA as a therapeutic target.
前列腺特异性膜抗原(PSMA)是一种在前列腺癌细胞中表达的重要生物标志物,其水平与肿瘤分级成正比。膜结合以及与疾病分期的相关性预示着PSMA作为基于抗体疗法的抗原靶点具有广阔前景。成功应用此类疗法需要详细了解靶抗原的亚细胞定位和运输情况。在本研究中,我们发现PSMA主要在前列腺腺上皮细胞的顶端质膜以及分化良好的Madin-Darby犬肾细胞中表达。我们表明PSMA直接靶向顶端表面,并且分选到合适的高尔基体后囊泡取决于该蛋白的N-糖基化。微管细胞骨架的完整性对于PSMA在顶端质膜结构域的递送和保留也至关重要,因为用诺考达唑或常用化疗药物长春花生物碱破坏微管会导致PSMA在基底外侧表达,并增加基底外侧结构域对抗PSMA抗体的摄取。这些结果可能与基于PSMA的免疫疗法和成像策略具有重要相关性,因为前列腺癌细胞即使转移到远处部位后仍可保持良好的分化形态。与基底外侧表面的抗原不同,顶端抗原通过限制分子跨上皮运输的紧密连接与循环系统分隔开。因此,顶端质膜上表达的抗原不会暴露于静脉内给药的药物中。将PSMA的极性从顶端反转至基底外侧的能力可能对将PSMA用作治疗靶点具有重大意义。